Stockscreener 앱 받기
40.45
1.15%
0.46
시간 외 거래:
40.45
전일 마감가:
$39.99
열려 있는:
$39.99
하루 거래량:
413.30K
Relative Volume:
0.64
시가총액:
$1.73B
수익:
$17.39M
순이익/손실:
$-135.89M
주가수익비율:
-8.7177
EPS:
-4.64
순현금흐름:
$-123.00M
1주 성능:
+0.62%
1개월 성능:
-7.75%
6개월 성능:
-26.65%
1년 성능:
+46.82%
1일 변동 폭
$39.40
$41.06
1주일 범위
$39.19
$41.50
52주 변동 폭
$20.08
$57.28
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
명칭
Tarsus Pharmaceuticals Inc
전화
(949) 409-9820
주소
15440 LAGUNA CANYON ROAD, IRVINE
TARS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
40.45 | 1.73B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-27 | 재개 | H.C. Wainwright | Buy |
| 2023-11-20 | 개시 | Goldman | Neutral |
| 2023-07-18 | 개시 | William Blair | Outperform |
| 2023-05-18 | 개시 | Guggenheim | Buy |
| 2022-08-01 | 개시 | Barclays | Overweight |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-23 | 개시 | Oppenheimer | Outperform |
| 2020-11-10 | 개시 | BofA Securities | Buy |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Ladenburg Thalmann | Buy |
| 2020-11-10 | 개시 | Raymond James | Strong Buy |
모두보기
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
Tarsus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Tarsus Pharmaceuticals Becomes Oversold (TARS) - Nasdaq
When (TARS) Moves Investors should Listen - news.stocktradersdaily.com
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Rhumbline Advisers Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals’ SWOT analysis: XDEMVY’s success propels stock growth - Investing.com Australia
Tarsus Pharmaceuticals’ SWOT analysis: XDEMVY’s success propels stock growth By Investing.com - Investing.com India
Insider Sell: Aziz Mottiwala Sells 17,500 Shares of Tarsus Pharm - GuruFocus
Tarsus Pharmaceuticals CCO sells $765,800 in stock - Investing.com Australia
Tarsus Pharmaceuticals CCO sells $765,800 in stock By Investing.com - Investing.com Canada
Certain Common stock of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2025. - marketscreener.com
Certain Stock Options of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2025. - MarketScreener
Tarsus Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Focus By Investing.com - Investing.com Canada
Transcript : Tarsus Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 01 - MarketScreener
Stocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS Rating - MSN
Squarepoint Ops LLC Sells 51,329 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Where are the Opportunities in (TARS) - news.stocktradersdaily.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Oppenheimer - Defense World
Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $72, Maintains Outperform Rating - marketscreener.com
TARS: Oppenheimer Ups Tarsus Pharmaceuticals Price Target to $75 | TARS Stock News - GuruFocus
TARS: Oppenheimer Ups Tarsus Pharmaceuticals Price Target to $75 - GuruFocus
What is HC Wainwright’s Estimate for TARS Q2 Earnings? - Defense World
Nuveen Asset Management LLC Sells 15,186 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus to Participate in Upcoming Investor Conferences | TARS Stock News - GuruFocus
Tarsus Lines Up Triple Conference Appearances: William Blair, Jefferies, and Goldman Sachs in June - Stock Titan
Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Ameriprise Financial Inc. - Defense World
BNP Paribas Financial Markets Buys New Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Upgraded by HC Wainwright - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by HC Wainwright - Defense World
TARS: HC Wainwright & Co. Initiates Buy Rating with $72 Target | - GuruFocus
Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
TARS: HC Wainwright & Co. Initiates Buy Rating with $72 Target | TARS Stock News - GuruFocus
TARS: H.C. Wainwright Initiates Coverage with a Buy Rating | TARS Stock News - GuruFocus
Tarsus Pharmaceuticals Advances Novel Treatments for Eye and Vector-Borne Diseases - utahdailynewswire.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $1.16 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Bank of America Corp DE - Defense World
Tarsus Pharmaceuticals at H.C. Wainwright: Expanding Horizons with Xdemvy By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals Shows Rising Price Performance With Jump To 84 RS Rating - inkl
When the Price of (TARS) Talks, People Listen - news.stocktradersdaily.com
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Tarsus Pharmaceuticals Inc Enters Oversold Territory (TARS) - Nasdaq
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Northern Trust Corp - Defense World
Transcript : Tarsus Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
Tarsus Pharmaceuticals Breaks Below 200-Day Moving AverageNotable for TARS - Nasdaq
Tarsus Pharmaceuticals (TARS) Expected to Announce Earnings on Wednesday - Defense World
Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off (NASDAQ:TARS) - Seeking Alpha
Tarsus to Participate in Upcoming Investor Conferences | TARS St - GuruFocus
Dimensional Fund Advisors LP Sells 62,658 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals Reports First Quarter 2025 Sales Growth - VisionMonday.com
Tarsus Pharmaceuticals Inc (TARS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):